Dexcom Inc - DXCM STOCK NEWS

Dexcom, Beyond Type 2, and actress Retta are establishing National Glucose Awareness Week from Sept. 23-29, 2024. This initiative aims to close the glucose knowledge gap and encourage people to take action on their glucose health. The week will feature educational resources about glucose health and information on new glucose biosensing technology.

A recent survey found that only 10% of people with Type 2 diabetes or prediabetes understand factors affecting their glucose levels well. The initiative includes a nationwide step challenge and opportunities to win prizes while learning about glucose health. Retta, who manages Type 2 diabetes, will inspire others to get involved.

The campaign targets not only those diagnosed with diabetes or prediabetes but also aims to raise awareness among the general population, as one-third of the U.S. population has diabetes or prediabetes, with many unaware of their condition.

Dexcom (NASDAQ: DXCM) has launched the third season of Dexcom U, its NIL program for college athletes with diabetes. The 2024 roster includes 20 athletes across 12 sports from 18 colleges, all using Dexcom CGM technology. The program has expanded its mentorship initiatives, including the first-ever Dexcom U Sports Camp, bringing together professional athletes, Dexcom U members, and young athletes with diabetes.

Dexcom U aims to inspire and educate the diabetes community through representation and mentorship. The program provides free educational resources for athletes, parents, coaches, and teammates to better understand diabetes management in sports. Notable additions to the roster include Shelomi Sanders, a basketball player at Alabama A&M, highlighting the program's commitment to diverse representation in collegiate athletics.

Dexcom's G6 Continuous Glucose Monitoring (CGM) System is being used by astronauts on the Polaris Dawn mission to study the effects of spaceflight on human health, particularly glucose regulation. This marks a significant milestone for Dexcom (NASDAQ: DXCM) as the first use of their CGM technology in space. The mission will conduct about 40 scientific experiments over five days, exploring how microgravity and space conditions impact glucose health.

Dexcom is collaborating with Labfront to provide advanced analytics for the collected data. This research is important for understanding metabolic responses in space and ensuring space travel is inclusive for people with diabetes. The company recently launched Stelo, the first FDA-cleared glucose biosensor for non-prescription use by adults not using insulin, further expanding their portfolio of glucose monitoring solutions.

Dexcom (NASDAQ: DXCM) is set to showcase its Continuous Glucose Monitoring (CGM) technology at the EASD 2024 Conference Symposium. The event will feature expert panelists discussing the transformational effects of Dexcom CGM on clinical practice. Key highlights include:

1. Dexcom's position as the most experienced partner in Automatic Insulin Delivery (AID), powering more AID systems than any other CGM brand.

2. Studies showing Dexcom CGM's potential to support therapy de-escalation and optimize management in Type 2 diabetes.

3. Recent data indicating that 100% of Dexcom CGM users with Type 2 diabetes made dietary changes, and 91% felt empowered to manage their condition.

4. Evidence of long-term cost savings for healthcare systems across Europe.

Dexcom (NASDAQ: DXCM) has announced that its top executives will present at the 2024 Wells Fargo Healthcare Conference on September 4th. Kevin Sayer, Chairman, President and CEO, along with Jereme Sylvain, Executive VP and CFO, will provide an update on the company. The presentation is scheduled for 11:00 AM EST and will be webcast live.

Investors and interested parties can access the webcast through the Dexcom Investor Relations website at investors.dexcom.com. The presentation will also be archived on the site for future reference, allowing those unable to attend the live event to catch up later.

Dexcom has launched Stelo, the first over-the-counter glucose biosensor in the U.S., now available for purchase without a prescription at Stelo.com. Designed for people with Type 2 diabetes not using insulin and those with prediabetes, Stelo provides 24/7 glucose insights directly to a smartphone, revealing how food, exercise, and sleep affect glucose levels.

Key features of Stelo include:

• No fingersticks required
• Up to 15-day wear time
• Waterproof design
• Personalized app with spike and pattern detection
• Proven results in lowering A1c and potentially slowing diabetes progression

Dexcom, Inc. (NASDAQ: DXCM) announced that its Dexcom G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan. This expansion brings coverage to Québec residents ages two and older living with type 1 diabetes who meet eligibility criteria. Launched in Canada in 2023, Dexcom G7 is described as the most accurate CGM system available, clinically proven to lower A1C and increase time in range. The system allows users to easily monitor glucose levels and make informed decisions about insulin, food, and activity without routine fingersticks or scanning. This coverage expansion follows similar announcements in other Canadian provinces, making advanced diabetes management technology more accessible and reducing out-of-pocket costs for eligible individuals.

Tandem Diabetes Care and Dexcom have announced that the t:slim X2 insulin pump with Dexcom G7 CGM compatibility has been authorized for sale by Health Canada. This integration makes it the only Automated Insulin Delivery (AID) system in Canada compatible with both Dexcom G7 and G6 CGM technologies. The updated software is expected to be commercially available this fall, with existing users receiving a free remote update.

Key features of the integration include:

• Dexcom G7's smaller, all-in-one sensor and transmitter
• 30-minute sensor warmup time
• 12-hour grace period for sensor replacement
• Increased connectivity with digital health apps

The t:slim X2 pump with Control-IQ technology is rated as the #1 AID system in Canada, offering customizable profiles and various infusion set options.

Dexcom reported its Q2 2024 financial results, with revenue growing 15% year-over-year to $1.004 billion. U.S. revenue grew 19% while international revenue increased 7%. GAAP operating income was $158.0 million, or 15.7% of revenue. The company updated its 2024 guidance, projecting revenue of $4.00-4.05 billion (11-13% organic growth). Dexcom also announced a $750 million share repurchase program.

Strategic highlights include launching Direct-to-Watch in the U.S. and international markets, securing coverage for Dexcom ONE in France for type 2 diabetes patients on basal insulin, and advancing pump connectivity with Insulet and Tandem Diabetes Care. However, CEO Kevin Sayer noted that execution did not meet their high standards, and the company is taking action to improve.